Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

AIM Price Correlated With Financials For AIM ImmunoTech

Free historical financial statements for AIM Immunotech Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with AIM stock chart to see long term trends.

AIM Stock Compared to Quarterly

AIM Income Statement

Revenue, Net:33000
Revenue Per Share:0.0007
Selling, General & Admin Expense:2072000
Research & Development Expense:1036000
Total Operating Expenses:3185000
Operating Income:-3152000
Net Income:-3820000
Earnings Per Share, Basic:-0.08
Shares Outstanding, Basic Avg:48048822

AIM Cash Flow

Operating Activities Net Income:
Net Cash from Operations:-2758000
Net Cash from Operations Per Share:-0.0574
Net Cash from Financing Activities:null
Net Cash from Investing Activities:-346000
Net Change in Cash & Equivalents:-3104000

AIM Balance Sheet

Cash and Cash Equivalents:28989000
Short-Term Investments:15554000
Accounts Receivable, Net:null
Total Current Assets:50380000
Property, Plant & Equipment, Net:137000
Total Assets:54155000
Accounts Payable:378000
Total Short-Term Liabilities:766000
COMPANY PROFILE
(1) Business

AIM
ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

AIM’s
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”).

The
Company’s primary present business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being
developed for globally important cancers, viral diseases and disorders of the immune system.

AIM
currently is proceeding primarily in three areas:

● Ampligen
plus Standard of Care (“SOC”) to treat pancreatic cancer patients, and in other
cancers, as a potential therapeutic that modifies the tumor microenvironment with the goal
of increasing anti-tumor responses to check point inhibitors and with SOC.

● Exploring
Ampligen’s antiviral activities and potential use as a prophylactic or treatment for
existing viruses, mutations thereof or new viruses.

● Ampligen
as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”)
and what we refer to as Post-COVID-19 Cognitive Impairment.

Today,
some two years after COVID-19 first appeared, the world has a number of vaccines and some promising therapeutics. AIM’s quest to
prove the antiviral activities of Ampligen continues. If Ampligen has the broad-spectrum antiviral properties that the Company believes
that it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that
arise in the future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. AIM believes that it activates
antiviral immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.

Alferon
N Injection is approved in Argentina for a category of sexually transmitted disease infections and patients that are not responsive or
are intolerant to recombinant interferon. Alferon N Injection is the only natural-source, multi-species alpha interferon currently approved
for sale in the United States for the intralesional treatment of refractory (i.e., resistant to other treatment) or recurring external
condylomata acuminata/genital warts in patients 18 years of age or older. Certain types of human papilloma viruses cause genital warts.
AIM also has approval from ANMAT for the treatment of refractory patients that failed or were intolerant to treatment with recombinant
interferon in Argentina.

The
Company recently announced the sale of its 30,000
sq. ft. facility at 783 Jersey
Ave, New Brunswick, N.J., where it conducts testing and has produced limited quantities of active pharmaceutical ingredients (“API”)
for its products. While the Company believes it has sufficient API to meet its current needs, it is also continually exploring new opportunities
to maximize its ability to fulfill future needs. AIM’s current and active produc

Data imported from AIM Immunotech Inc. SEC filings. Check original filings before making any investment decision.